Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$522K Sell
2,324
-225
-9% -$56.1K 0.08% 120
2025
Q4
$614K Sell
2,549
-100
-4% -$25.6K 0.09% 112
2025
Q3
$725K Buy
2,649
+9
+0.3% +$2.46K 0.11% 99
2025
Q2
$681K Buy
2,640
+121
+5% +$28.9K 0.11% 100
2025
Q1
$564K Sell
2,519
-77
-3% -$18K 0.09% 111
2024
Q4
$594K Buy
+2,596
New +$625K 0.1% 106

Other funds holding RMD

CFO4Life Group's RMD Position: Q1 2026 in Review

CFO4Life Group reduced its ResMed (RMD) stake by 8.8% in Q1 2026, selling an estimated $56.1K and leaving 2,324 shares worth $522K. The position accounts for 0.08% of the portfolio, ranked #120.

CFO4Life Group first reported a position in RMD in Q4 2024 and has held it in 6 quarters since. The position peaked at $725K in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • CFO4Life Group held 2,324 shares of ResMed worth $522K as of Q1 2026.
  • CFO4Life Group sold 225 ResMed shares in Q1 2026, an estimated $56.1K.
  • ResMed made up 0.08% of CFO4Life Group's portfolio in Q1 2026, its #120 holding.
  • CFO4Life Group first reported a position in ResMed in Q4 2024 and has held it in 6 quarters since.
  • CFO4Life Group's ResMed position peaked at $725K in Q3 2025.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on CFO4Life Group's 13F filing for Q1 2026, filed 11 May 2026.